Research reference
P21 (Cerebrolysin alternative)
A reference record for P21 (Cerebrolysin alternative). Its exact identity is unresolved after targeted source searches on 6 September 2026.
Source and review status
Identity unresolved
Identity search checked on: 6 September 2026
Qualified clinical review: Pending. This page has not been clinically reviewed.
About this source check
AI-assisted editorial source checking covers the cited material and its stated limits. It is not a systematic review, verification of a supplied product, or clinical sign-off.
Editorial role: InfoAddict. Last material change: 6 September 2026. Next source review: 6 December 2026.
Identity status
Primary P021 literature concerns a defined CNTF-derived peptide mimetic. A label describing a “Cerebrolysin alternative” does not identify that molecule or establish equivalence to Cerebrolysin, which is a separate mixture.
Evidence boundary
No efficacy, mechanism, human-study, safety or product-quality claim is included while the material cannot be matched reliably to one substance.
What would resolve it
A written sequence or structure, terminal modifications and a stable primary, chemical or regulator record would allow this entry to be revised.
Until then, this remains a label-level record rather than a substance reference.
Source search outcome
No published source was matched confidently to this exact catalogue label. Related names have not been substituted as evidence. The identity limits above explain what remains uncertain.
Change history
| Date | Change | Clinical-review status |
|---|---|---|
| 6 September 2026 | Identity and evidence limits documented | Pending |
Keep a private record
UpgradeYourself lets you keep private records of routines and observations you choose to discuss with a qualified health professional. This reference does not recommend starting, stopping or changing an item.